Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: GlobeNewswire
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development. Both will report to Paul Hadden, Ligand’s Senior Vice President of Investments and Business Development. Dr. Renehan comes to the firm from Blackstone Life Sciences, where he served as a Principal. He was previously in healthcare investment banking with Lazard, Inc., and in corporate strategy at Moderna Therapeutics and Flagship Pioneering. Mr. Brown joins Ligand from Third Bridge Group, where he served as Global Team Leader for Healthcare. He was the founder and Chief Investment Officer of Reef Knot Capital and served as a Portfolio Manager at Visium Asset Management. Both Dr. Renehan and Mr. Brown will be responsible for sourcing and transacting royalty financing opportunities. As part of the team build-out, Lauren Hay is
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals (LGND) had its price target raised by Citigroup Inc. from $270.00 to $276.00. They now have a "buy" rating on the stock.MarketBeat
- Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model [Seeking Alpha]Seeking Alpha
- Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals (LGND) is now covered by Bank of America Corporation. They set a "buy" rating and a $244.00 price target on the stock.MarketBeat
- How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth [Yahoo! Finance]Yahoo! Finance
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/25/26 - Form 4
- 3/23/26 - Form 144
- LGND's page on the SEC website